Voyager Therapeutics Approves Stock Plans at Annual Meeting

Voyager Therapeutics ( (VYGR) ) has issued an update.

At the annual meeting held on June 3, 2025, Voyager Therapeutics‘ stockholders approved the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan, both previously adopted by the Board of Directors. Additionally, stockholders elected four Class I directors to serve until the 2028 meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (VYGR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.

Spark’s Take on VYGR Stock

According to Spark, TipRanks’ AI Analyst, VYGR is a Neutral.

The most significant factor impacting Voyager Therapeutics’ score is its financial performance, marked by revenue declines and ongoing profitability issues. Technical analysis shows some neutral momentum but no strong positive signals. Valuation concerns, driven by a negative P/E ratio and lack of dividend yield, further impact the overall score.

To see Spark’s full report on VYGR stock, click here.

More about Voyager Therapeutics

Voyager Therapeutics, Inc. operates in the biotechnology industry, focusing on developing gene therapies for neurological diseases. The company aims to address severe diseases by leveraging its proprietary platform technologies.

Average Trading Volume: 455,947

Technical Sentiment Signal: Sell

Current Market Cap: $181.5M

See more data about VYGR stock on TipRanks’ Stock Analysis page.